Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 

All-cause mortality after five years is much more likely if a TAVR patient presents with CAD, according to a new analysis published in JACC: Cardiovascular Interventions.

After finding success in Europe, the company is focused on gaining FDA approval for its Trilogy Heart Valve System and launching the device in the United States. 

Though removal of the affected CIED is typically the smartest treatment option—and one supported by specialty groups all over the world—a majority of patients keep living with the device, often resulting in hospitalization or even death.

Affera’s portfolio includes interventional solutions such as the Affera Prism-1 mapping and navigation platform, designed to help electrophysiologists diagnose heart rhythm issues, and the Sphere-9 cardiac ablation catheter. 

The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health. 

New research, published in JAMA Cardiology, challenges the common belief that AFib is more likely to develop among men than women. The key problem, it seems, is that prior research teams did not understand the significance of certain risk factors.

A new consensus statement from the Society of Cardiovascular Computed Tomography emphasized the increasing importance of CCTA among interventional cardiologists. It is no longer seen as “a mere diagnostic tool," the group observed.